Nurix Therapeutics, Inc.
NRIX
$13.59
$0.403.03%
| 11/30/2024 | 08/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 5.53% | 4.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 5.53% | 4.10% | |||
| Cost of Revenue | 21.17% | 13.41% | |||
| Gross Profit | -25.75% | -16.46% | |||
| SG&A Expenses | -8.54% | 0.07% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.99% | 10.83% | |||
| Operating Income | -18.40% | -12.51% | |||
| Income Before Tax | -19.78% | -9.94% | |||
| Income Tax Expenses | -90.24% | -8.89% | |||
| Earnings from Continuing Operations | -19.60% | -9.90% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -19.60% | -9.90% | |||
| EBIT | -18.40% | -12.51% | |||
| EBITDA | -21.43% | -13.00% | |||
| EPS Basic | -11.00% | 5.80% | |||
| Normalized Basic EPS | -11.17% | 5.77% | |||
| EPS Diluted | -11.00% | 5.80% | |||
| Normalized Diluted EPS | -11.17% | 5.77% | |||
| Average Basic Shares Outstanding | 7.74% | 16.68% | |||
| Average Diluted Shares Outstanding | 7.74% | 16.68% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
